Dysbetalipoproteinemia: Difference between revisions

Jump to navigation Jump to search
Line 35: Line 35:


=Physical Exam=
=Physical Exam=
Physical examination in dybetalipoproteinemia may be normal
Physical examination in dybetalipoproteinemia may range from being normal to the presence of these findings<ref name="pmid12506591">{{cite journal| author=Blom DJ, Byrnes P, Jones S, Marais AD| title=Dysbetalipoproteinaemia--clinical and pathophysiological features. | journal=S Afr Med J | year= 2002 | volume= 92 | issue= 11 | pages= 892-7 | pmid=12506591 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12506591  }} </ref>
 
*Xanthoma Striatum Palmare-consisting of yellow streaks in the palmar creases.
*Xanthoma Striatum Palmare-consisting of yellow streaks in the palmar creases.
*Tuberoeruptive xanthomas on the elbow or tibial tuberosities
*Tuberoeruptive xanthomas on the elbow or tibial tuberosities
*Tendon xanthomas may also be seen rarely.
*Cutaneous xanthomas
*Tendon xanthomas may also be seen rarely


=Laboratory Findings=
=Laboratory Findings=

Revision as of 19:56, 9 November 2016

Overview

Classification

Historical perspective

Pathophysiology

Causes

Differential Diagnoses

Epidemiology and Demographics

Screening

Natural History, Complication, Prognosis

Complications

Dysbetalipoprtenemia can cause the following complications [1]

  • Atherosclerotic complications like ischemic heart disease
  • Pancreatitis
  • Stroke
  • Peripheral vascular disease
  • Intermittent claudication
  • Gangrene of the lower extremities

Prognosis

  • Patients with dysbetalipoproteinemia have an increased risk for coronary artery disease and peripheral vascular disease.
  • With treatment, most people show a significant reduction in lipid levels.

Diagnosis

Diagnosis of dysbetalipoprotenemia is confirmed[2] by the

  • Presence of a palmar crease xanthoma, which is a rare diagnostic finding of dysbetalipoproteinemia.
  • Lipid profile
  • Genotyping apoE. apo E-2 presence causes defective binding of apo E containing lipid particles.
  • Ultracentrifugation or nuclear magnetic resonance lipid profiling

History and Symptoms

Symptoms of dysbetalipoprotenemia include

Physical Exam

Physical examination in dybetalipoproteinemia may range from being normal to the presence of these findings[1]

  • Xanthoma Striatum Palmare-consisting of yellow streaks in the palmar creases.
  • Tuberoeruptive xanthomas on the elbow or tibial tuberosities
  • Cutaneous xanthomas
  • Tendon xanthomas may also be seen rarely

Laboratory Findings

Molecular Genetic Testing

The laboratory findings consistent with dysbetalipoprotenemia include[3]the following

Appearance VLDL cholesterol Cholesterol Triglycerides Isoelectric focusing
Floating

beta lipoproteins

VLDL cholesterol

>0.35

Elevated Elevated ApoE-2 homozygote

Treatment

Medical Therapy

Dysbetalipoprotenemia can be treated[4] with

  • Bile acid binding agents are an option if TG levels are <200mg/dL
  • Statins can be used if TG levels are <500mg/dL
  • Fibrates and Nicotinic acid can otherwise be used.

Prevention

  • Screening the family members of those with familial dysbetalipoproteinemia may lead to early detection and treatment.
  • Early treatment and avoiding other risk factors for vascular disease (such as smoking) are crucial to preventing early heart attacks, strokes, and blocked blood vessels.

References

  1. 1.0 1.1 Blom DJ, Byrnes P, Jones S, Marais AD (2002). "Dysbetalipoproteinaemia--clinical and pathophysiological features". S Afr Med J. 92 (11): 892–7. PMID 12506591.
  2. Rothschild M, Duhon G, Riaz R, Jetty V, Goldenberg N, Glueck CJ; et al. (2016). "Pathognomonic Palmar Crease Xanthomas of Apolipoprotein E2 Homozygosity-Familial Dysbetalipoproteinemia". JAMA Dermatol. doi:10.1001/jamadermatol.2016.2223. PMID 27603268.
  3. Braunwald, Eugene. Heart Disease- Fourth Edition. Harvard Medical School: W. B. SAUNDERS COMPANY. p. 1137. ISBN 0-7216-3097-9.
  4. Hachem SB, Mooradian AD (2006). "Familial dyslipidaemias: an overview of genetics, pathophysiology and management". Drugs. 66 (15): 1949–69. PMID 17100406.


Template:WH Template:WS